Colagiuri S, presented a session at IDF World Diabetes Congress 2025 from 7th-10th April 2025 in Bangkok. Intermediate hyperglycemia (IH) includes IGT, IFG, and HbA1c. The WHO and ADA criteria for defining IH differ for IFG and the WHO does not have an HbA1c criterion. The 1-h OGTT has been recently advocated as an option. The general target of <7.0% (<53 mmol/mol) should ne personalised, balancing reducing complications, minimising hypoglycemia. HbA1c is important but has not been confirmed as an independent risk factor for complication.
Jaggi S, presented a session at IDF World Diabetes Congress 2025 from 7th-10th April 2025 in Bangkok. CGM has revolutionized the management of diabetes and is now widely acceptable. CGM technology has transformed diabetes care by offering real-time glucose monitoring and trend analysis. Smartphone apps and cloud connectivity enhance CGM data accessibility and clinical decision-making.
In most countries, especially in South Asia, the burden of diabetes and obesity has increased in past few decades. Anjana RM, presented a session at IDF World Diabetes Congress 2025 from 7th-10th April 2025 in Bangkok. In South Asians, type 2 diabetes tends to develop at least 10 years earlier and at significantly lower BMI levels compared to White Europeans.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with rising global prevalence and limited curative treatments. Through genetic integration using Mendelian randomization (MR) and genome-wide association studies (GWAS), 42 protein-coding genes were identified as being significantly associated with T2DM. Of these, six genes – CLSTN1, KCNJ11, MLX, DLD, RELA, and ULK1—shared common causal variants with the disease, indicating potential as drug targets.
Recent prescription trends for novel heart failure medications were analyzed at a major Kansas City safety net hospital, focusing on the utilization patterns of sacubitril/valsartan and SGLT2 inhibitors in underserved populations. The study examined prescription data from October 2021 to October 2022, involving 769 patients receiving sacubitril/valsartan and 2,287 patients prescribed SGLT2 inhibitors.
